Prometheus Laboratories Appoints Chief Executive Officer

           Prometheus Laboratories Appoints Chief Executive Officer

PR Newswire

SAN DIEGO, Sept. 19, 2013

SAN DIEGO, Sept. 19, 2013 /PRNewswire/ -- Prometheus Laboratories Inc., a
specialty pharmaceutical and diagnostic company announced today that Ms. Lisa
Miller has been appointed to the position of Chief Executive Officer.

With more than 25 years of experience in the global diagnostic and devices
industries, Ms. Miller most recently served as Corporate Vice President at
DAKO, an Agilent Technologies Company, headquartered in Copenhagen, Denmark.
She was responsible for global operations of their cancer diagnostics
business, with $375M in revenue and over 500 employees worldwide. She was also
a member of the Board of Directors and Corporate Management Team. Under her
leadership, Ms. Miller redefined DAKO's strategy and restructured the
commercial operations of the company, resulting in its 2012 acquisition by
Agilent Technologies.

Prior to joining DAKO, Ms. Miller was with Invitrogen Corporation, in the
position of Vice President, Commercial Business and head of the Americas
region. Prior to this, she held several positions of increasing commercial
responsibility at Thermo Fisher Scientific, most recently as Vice President
Sales with accountability for a $600M business. During her tenure at Thermo
Fisher, Ms. Miller held several senior sales and account management positions
focused on growth and business development through contractual relationships
with major pharmaceutical companies.

Ms. Miller commented: "I am very enthusiastic about joining Prometheus to
drive our diagnostic strategy across the chosen therapeutic platforms. I
believe Prometheus plays a key role in Nestle Health Science's ambition to
create a new segment in health care, using diagnostic and nutrition science
solutions in the management of disease."

"We are delighted to have Ms. Miller join our team," commented Cathy Kerzner,
interim CEO of Prometheus. "We anticipate she will make a tremendous
contribution to our growth strategy, with her depth in diagnostics along with
her proven record of performance.'

About Prometheus
Prometheus Laboratories Inc. is committed to improving lives through the
development and commercialization of novel pharmaceutical and diagnostic
products that enable physicians to provide greater individualized patient
care. Prometheus is a leader in applying the principles of personalized
medicine to the diagnosis and treatment of gastrointestinal diseases and is
applying these principles to oncology. Its strategy includes the marketing and
delivery of pharmaceutical products complemented by proprietary diagnostic
testing services. By integrating therapeutics and diagnostics, Prometheus
believes it can provide physicians with more targeted solutions to optimize
care for their patients. Prometheus became part of Nestle Health Science in
July 2011. The corporate offices of Prometheus are located in San Diego,
California. For more information about Prometheus, please visit
www.prometheuslabs.com.

About Nestle Health Science
Nestle Health Science, a wholly-owned subsidiary of Nestle, intends to
spearhead the development of science-based personalised nutritional solutions.
Building on its core HealthCare Nutrition business, the company has ambitions
to address chronic conditions in the area of Gastrointestinal Health,
Metabolic Health and Brain Health. Nestle Health Science offers nutritional
solutions for people with specific dietary needs related to illnesses, disease
states or the special challenges of different life stages. Nestle Health
Science employs around 3,000 people worldwide and has its headquarters in
Vevey, Switzerland.For more information, please visit
www.nestlehealthscience.com.

SOURCE Prometheus Laboratories Inc.

Website: http://www.prometheuslabs.com
Website: http://www.nestlehealthscience.com
Contact: Beth Kriegel, Vice President, Finance & Strategy, Prometheus
Laboratories Inc., (858) 410-2516
 
Press spacebar to pause and continue. Press esc to stop.